Beta Bionics, Inc. (Ticker: BBNX) is a medical equipment and devices company incorporated in Delaware. The company designs, develops, and commercializes solutions to improve the health and quality of life of insulin-requiring people with diabetes. Their product, the iLet Bionic Pancreas, is an insulin delivery device cleared by the FDA to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake.

Beta Bionics, Inc. will list on January 30, 2025, on NASDAQ. The firm is selling 10.0 million shares at the price range of $16-17. The expected Market Capitalization at offer is $577.35 million. The total offer size is $165.0 million. The offering is managed by BofA Securities/Piper Sandler/Leerink/Stifel.